注意缺陷多动障碍药物对行为与神经精神结局的风险与获益:基于处方链接数据库的药物流行病学研究定性综述
本文对近10年使用链接处方数据库的40项药物流行病学研究进行定性系统综述,其中18项采用个体内设计控制适应证混杂。结果显示ADHD药物对伤害、机动车事故、教育、物质使用障碍等结局有短期获益,相对风险降低9%至58%,个体内研究未发现自杀和癫痫风险增加。长期效应证据尚不明确,需重复研究验证犯罪、抑郁、躁狂、精神病等结局。
要点
- ADHD药物对伤害、机动车事故、教育、物质使用障碍有短期获益,相对风险降低9%至58%。
- 个体内设计研究未发现ADHD药物增加自杀或癫痫风险。
- 长期效应证据不明确,犯罪、抑郁、躁狂、精神病等结局需重复研究。
核心结论
- ADHD药物对多种行为与神经精神结局显示短期获益,未发现自杀和癫痫风险增加,但长期效应证据不明确。
研究设计与样本
- 定性系统综述纳入近10年使用链接处方数据库的40项研究,来自欧洲、北美和亚洲,其中18项采用个体内设计控制适应证混杂。
主要发现
- ADHD药物对伤害、机动车事故、教育、物质使用障碍等结局有短期获益,相对风险降低9%至58%。
- 个体内设计研究未发现自杀和癫痫风险增加。
- 犯罪、抑郁、躁狂、精神病等其他重要结局需重复研究验证。
- ADHD药物长期效应的药物流行病学证据尚不明确。
临床怎么用
- 临床解读ADHD药物获益与风险时,应结合个体内设计证据并考虑时变混杂等局限性。
局限性
- 药物流行病学研究存在时变混杂等局限性,长期效应证据不明确,多个结局需重复研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Attention-deficit/hyperactivity disorder (ADHD) medication is one of the most commonly prescribed medication classes in child and adolescent psychiatry, and its use is increasing rapidly in adult psychiatry. However, major questions and concerns remain regarding the benefits and risks of ADHD medication, especially in real-world settings. We conducted a qualitative systematic review of studies that investigated the effects of ADHD medication on behavioral and neuropsychiatric outcomes using linked prescription databases from the last 10 years and identified 40 studies from Europe, North America, and Asia. Among them, 18 used within-individual designs to account for confounding by indication. These studies suggested short-term beneficial effects of ADHD medication on several behavioral or neuropsychiatric outcomes (i.e., injuries, motor vehicle accidents, education, substance use disorder), with estimates suggesting relative risk reduction of 9% to 58% for these outcomes. The within-individual studies found no evidence of increased risks for suicidality and seizures. Replication studies are needed for several other important outcomes (i.e., criminality, depression, mania, psychosis). The available evidence from pharmacoepidemiology studies on long-term effects of ADHD medication was less clear. We discuss time-varying confounding and other limitations that should be considered when interpreting results from pharmacoepidemiology studies. Furthermore, we highlight several knowledge gaps to be addressed in future research and implications for research on mechanisms of outcomes of ADHD medications.
引用
- Chang Z, Ghirardi L, Quinn PD, et al. Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases. Biol Psychiatry. 2019. PMID: 31155139. doi:10.1016/j.biopsych.2019.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。